<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2 Final//EN">
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+ 1.1a) -->
     <!-- Project:        F:\CONVER\ny11657.eep-->
     <!-- Control Number: form8k                                                           -->
     <!-- Rev Number:     8k                                                               -->
     <!-- Client Name:    1st Page                                                         -->
     <!-- Project Name:   Advanced Medical Optics Inc.                                                 -->
     <!-- Firm Name:      DO NOT EDIT THIS FORM                                            -->
     <TITLE>8K Form</TITLE>
</HEAD>
<BODY>

<BR><BR><BR>
<!-- MARKER FORMAT-SHEET="Width Begin" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>

<!-- MARKER FORMAT-SHEET="Head Center Bold 2" FSL="Project" -->
<H1 Align=CENTER><Font Face="Times New Roman, Times, Serif" Size=2>UNITED STATES<BR>SECURITIES AND
EXCHANGE COMMISSION<Br>Washington, D.C. 20549 </font></h1>

<!-- MARKER FORMAT-SHEET="Head Center Bold 2" FSL="Project" -->
<H1 Align=CENTER><Font Face="Times New Roman, Times, Serif" Size=2>FORM 8-K </font></h1>


<!-- MARKER FORMAT-SHEET="Width End" FSL="Project" -->
</TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CURRENT
 REPORT<BR>Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934  </FONT></H1></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Date
of Report (Date of earliest event reported): July 21, 2003  </FONT></TD></TR>
</TABLE>
<BR><BR>

<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b>ADVANCED
MEDICAL OPTICS, INC. </b><BR>(Exact name of registrant as specified in its charter) </FONT></TD>
</TR>
</TABLE>
<BR><BR>

<!-- MARKER FORMAT-SHEET="8k Cover table 3" FSL="Project" -->
<Table Width=600 Cellpadding=0 Cellspacing=0 Border=0>
<tr Valign=TOP>
<td Align=CENTER Width=33%><Font Face="Times New Roman, Times, Serif" Size=2><B>Delaware</B> </font></td>
<td Align=CENTER Width=34%><Font Face="Times New Roman, Times, Serif" Size=2><B>01-31257</B> </font></td>
<td Align=CENTER Width=33%><Font Face="Times New Roman, Times, Serif" Size=2><B>33-0986820</B> </font></td>
</tr>
<tr Valign=TOP>
<td Align=CENTER></td>
<td Align=CENTER></td>
<td Align=CENTER> </td>
</tr>
<tr Valign=TOP>
<td Align=CENTER><Font Face="Times New Roman, Times, Serif" Size=2>(State or other jurisdiction of<br> incorporation)
</font></td>
<td Align=CENTER><Font Face="Times New Roman, Times, Serif" Size=2>(Commission<br>File Number) </font></td>
<td Align=CENTER><Font Face="Times New Roman, Times, Serif" Size=2>(IRS Employer<br> Identification No.) </font></td>
</tr>
</table>
<br><BR>

<TABLE WIDTH="600" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="75" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>

    <TD WIDTH="350" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>1700
      E. St. Andrew Place<BR>
      Santa Ana, CA</B></FONT></TD>
     <TD WIDTH="100" ALIGN="CENTER" VALIGN="BOTTOM"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>92705</B></FONT></TD>
     <TD WIDTH="75" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD></TR>
<TR VALIGN="MIDDLE">
     <TD COLSPAN=4 WIDTH="600" ALIGN="CENTER"> </TD></TR>
<TR VALIGN="TOP">
     <TD WIDTH="75" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD WIDTH="350" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Address of principal executive offices) </FONT></TD>
     <TD WIDTH="100" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Zip Code)</FONT></TD>
     <TD WIDTH="75" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
<BR><BR>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Registrant's
telephone number, including area code: (714) 247-8200 </FONT></TD></TR>
</TABLE>
<BR>


<BR><BR>

<TABLE WIDTH="600" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>&nbsp;<!-- FORMER NAME OR ADDRESS --></B></FONT></TD></TR>
<TR VALIGN="MIDDLE">
     <TD WIDTH="600" ALIGN="CENTER"><HR NOSHADE SIZE=1 width=56%></TD></TR>
<TR VALIGN="TOP">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Former name or former address, if changed since last report) </FONT></TD></TR>
</TABLE><BR><BR><BR>

<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE>
<BR></TD></TR></TABLE>



<!-- MARKER FORMAT-SHEET="Head Left Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item
5.    &nbsp;&nbsp;&nbsp;&nbsp;Other Events and Required FD Disclosure.</FONT></H1></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On
July 21, 2003, the Registrant announced preliminary results of its modified Dutch auction
tender offer for its 9-1/4% Senior Subordinated Notes due 2010. The press release issued
with respect thereto is attached hereto as Exhibit 99.1 and by this reference incorporated
herein. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Default" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On
July 23, 2003, the Registrant announced final results of its modified Dutch auction tender
offer for its 9-1/4% Senior Subordinated Notes due 2010. The press release issued with
respect thereto is attached hereto as Exhibit 99.2 and by this reference incorporated
herein. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Head Left Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item
7.      &nbsp;&nbsp;&nbsp;&nbsp;  Financial Statements, Pro Forma Financial Information and Exhibits.</FONT></H1></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang 2" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(c)</FONT></TD>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=76%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Exhibits. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang 2" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>99.1</FONT></TD>
<TD WIDTH=76%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Press release of Registrant, dated July 21, 2003, with respect to preliminary results of
modified Dutch auction tender offer. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang 2" FSL="Default" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>99.2</FONT></TD>
<TD WIDTH=76%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Press release of Registrant, dated July 23, 2003, with respect to final results of
modified Dutch auction tender offer. </FONT></TD>
</TR>
</TABLE>
<BR>

<BR>
<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE>
<BR></TD></TR></TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SIGNATURES  </FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Default" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></TD></TR></TABLE><BR>





<!-- MARKER FORMAT-SHEET="Company Right" FSL="Project" -->
<TABLE WIDTH="600" BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD WIDTH="38"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; <!-- TYPE "DATE:" HERE--> </FONT></TD>
    <TD WIDTH="238"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="254"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"> <b>ADVANCED MEDICAL OPTICS, INC.</b> </FONT></TD>
  </TR>
</TABLE>
<BR><BR>

<!-- MARKER FORMAT-SHEET="Date By Signature" FSL="Project" -->
<TABLE WIDTH="600" BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD WIDTH="38"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Date: </FONT></TD>
    <TD WIDTH="219"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">July 23, 2003 </FONT></TD>
    <TD WIDTH="28"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="26"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">By: </FONT></TD>
    <TD WIDTH="238"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">/s/ Aimee S. Weisner </FONT></TD>
  </TR>
  <TR VALIGN="TOP">
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD>&nbsp; </TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD> <HR NOSHADE SIZE="1"> </TD>
  </TR>
</TABLE>

<!-- MARKER FORMAT-SHEET="Date By Signature" FSL="Project" -->
<TABLE WIDTH="600" BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD WIDTH="38"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"> </FONT></TD>
    <TD WIDTH="219"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; <!-- DATE--> </FONT></TD>
    <TD WIDTH="28"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="26"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="238"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Aimee S. Weisner, Corporate Vice President, General Counsel and Secretary </FONT></TD>
  </TR>
  <TR VALIGN="TOP">
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD>&nbsp; </TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD>&nbsp; </TD>
  </TR>
</TABLE>

<BR>

<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE>
<BR></TD></TR></TABLE>

<BR>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>INDEX
TO EXHIBITS </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang 2" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH="8%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2><U>Number</U></FONT></TD>
<TD WIDTH=76%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> <U>Exhibit</U> </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang 2" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>99.1</FONT></TD>
<TD WIDTH=76%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Press release of Registrant, dated July 21, 2003, with respect to preliminary results of
modified Dutch auction tender offer. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang 2" FSL="Default" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="LEFT"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>99.2</FONT></TD>
<TD WIDTH=76%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Press release of Registrant, dated July 23, 2003, with respect to final results of
modified Dutch auction tender offer. </FONT></TD>
</TR>
</TABLE>
<BR>

<BR>


<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE>
<BR></TD></TR></TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Right 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=RIGHT>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibit
99.1 </FONT></TD></TR>
</TABLE>
<BR>
<BR>

<!-- MARKER FORMAT-SHEET="Width Begin" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>

<TD><IMG SRC="amologo.jpg" ALIGN="RIGHT">

<!-- MARKER FORMAT-SHEET="Width End" FSL="Project" -->
</TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Left 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>FOR
IMMEDIATE RELEASE</B> <BR>Advanced
Medical Optics, Inc.<BR>
Contact:&nbsp;&nbsp;Vince Scullin<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(714) 247-8344<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 vince.scullin@amo-inc.com </FONT></P></TD></TR>
</TABLE>
<BR>
<BR>

<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ADVANCED
MEDICAL OPTICS, INC. ANNOUNCES<BR>PRELIMINARY RESULTS OF MODIFIED DUTCH AUCTION TENDER
OFFER  <BR>FOR ITS 9-1/4% SENIOR SUBORDINATED NOTES </FONT></H1></TD></TR>
</TABLE>
<BR>



<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(SANTA
ANA, CA), July 21, 2003 &#151; Advanced Medical Optics, Inc. [NYSE: AVO] (&#147;AMO&#148;)
today announced preliminary results of its &#147;Modified Dutch Auction&#148; tender offer
(the &#147;Offer&#148;) for up to $115.0 million aggregate principal amount at maturity
(the &#147;Offer Amount&#148;) of its outstanding 9-1/4% Senior Subordinated Notes due
2010 (the &#147;Notes&#148;). The Offer commenced on June 18, 2003 and expired at 12:00
midnight on July 18, 2003 (the &#147;Expiration Date&#148;). </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>As
of the Expiration Date, the Depositary for the Offer reported that approximately $177.6
million aggregate principal amount at maturity of Notes had been properly tendered by
holders of Notes (including $500,000 aggregate principal amount at maturity tendered
through notice of guaranteed delivery) at or below the maximum offer price of $1,150 per
$1,000 aggregate principal amount at maturity of Notes. Due to the over-subscription, in
accordance with the terms of the Offer, AMO expects to purchase (i) all Notes tendered
below the purchase price and (ii) Notes tendered at the purchase price on a pro rata basis
in an amount that will enable the Company to purchase the full $115.0 million aggregate
principal amount at maturity of Notes subject to the Offer. AMO will pay the same purchase
price for all Notes accepted for payment in the Offer. Based on the preliminary results,
AMO expects the purchase price to be the maximum offer price of $1,150 per $1,000
aggregate principal amount at maturity of Notes and expects the pro-ration factor to be
approximately 11%. The actual purchase price and pro-ration factor will be announced
promptly following completion of the verification process. Final determination of the
actual aggregate principal amount at maturity of Notes to be purchased is subject to final
delivery and final confirmation. Any Notes not accepted for payment will be promptly
returned to holders. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Morgan
Stanley &amp; Co. Incorporated acted as exclusive dealer manager, Mellon Investor Services
LLC acted as information agent and The Bank of New York acted as depositary in connection
with the Offer. </FONT></TD></TR></TABLE>

<BR>
<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>About
Advanced Medical Optics</B><BR>Advanced
Medical Optics, Inc. (AMO) is a global leader in the development, manufacturing and
marketing of ophthalmic surgical and eye care products. The Company focuses on developing
a broad suite of innovative technologies and devices to address a wide range of eye
disorders. Products in the ophthalmic surgical line include foldable intraocular lenses,
phacoemulsification systems, viscoelastics and related products used in cataract surgery,
and microkeratomes used in LASIK procedures for refractive error correction. AMO owns or
has the rights to such well-known ophthalmic surgical product brands as PhacoFlex&reg;,
Clariflex&reg;, Array&reg; and Sensar&reg; foldable intraocular lenses, the Sovereign&reg;
phacoemulsification system and the Amadeus&#153; microkeratome. Products in the eye care
line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting
drops. Among the well-known eye care product brands the Company possesses are
COMPLETE&reg;, COMPLETE&reg; Blink-N-Clean&reg;, Consept&reg;F, Consept&reg; 1 Step,
Oxysept&reg; 1 Step, Ultracare&reg;, Ultrazyme&reg;, Total Care&reg; and blink&#153;.
Amadeus&#153; is a licensed product of, and a trademark of, SIS, Ltd. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Advanced
Medical Optics, Inc. is based in Santa Ana, California, and employs approximately 2,000
worldwide. The Company has operations in about 20 countries and markets products in
approximately 60 countries. For more information, visit the Company&#146;s web site at
www.amo-inc.com. </FONT></TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Forward-Looking
Statements</B><BR>This press release contains forward-looking statements about AMO, including those relating to
the Offer. All forward-looking statements in this press release are based on estimates and
assumptions and represent AMO&#146;s judgment only as of the date of this press release.
Actual results may differ from current expectations based on a number of factors including
but not limited to changing market conditions and matters generally affecting the domestic
and global economy, such as changes in interest and currency exchange rates. Therefore,
the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any
intent or obligation to update these forward-looking statements. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Default" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Additional
information concerning these and other risk factors may be found in previous financial
press releases issued by AMO. AMO&#146;s public periodic filings with the Securities and
Exchange Commission, including the discussion under the heading &#147;Certain Factors and
Trends Affecting AMO and its Businesses&#148; in AMO&#146;s 2002 Form 10-K filed by AMO
with the Securities and Exchange Commission on March 14, 2003 and in AMO&#146;s Form 10-Q
for the quarter ended March 28, 2003 filed by AMO with the Securities and Exchange
Commission on May 5, 2003, also include information concerning these and other risk
factors. Copies of press releases and additional information about AMO are available on
the World Wide Web at www.amo-inc.com, or you can contact the AMO Investor Relations
Department by calling the number listed below. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>#&nbsp;&nbsp;#&nbsp;&nbsp;#&nbsp;&nbsp; </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE>
<BR></TD></TR></TABLE>


<!-- MARKER FORMAT-SHEET="Head Right 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=RIGHT>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibit
99.2 </FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Width Begin" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>

<TD><IMG SRC="amologo.jpg" ALIGN="RIGHT">

<!-- MARKER FORMAT-SHEET="Width End" FSL="Project" -->
</TD>
</TR>
</TABLE>
<BR>
<!-- MARKER FORMAT-SHEET="Head Left 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>FOR
IMMEDIATE RELEASE</B> <BR>Advanced
Medical Optics, Inc.<BR>
Contact:&nbsp;&nbsp;Vince Scullin<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(714) 247-8344<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 vince.scullin@amo-inc.com </FONT></P></TD></TR>
</TABLE>
<BR>

<BR>
<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ADVANCED
MEDICAL OPTICS, INC. ANNOUNCES<BR>FINAL RESULTS OF MODIFIED DUTCH AUCTION TENDER OFFER <BR>
FOR ITS 9-1/4% SENIOR SUBORDINATED NOTES </FONT></H1></TD></TR>
</TABLE>



<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(SANTA
ANA, CA), July 23, 2003 &#151; Advanced Medical Optics, Inc. [NYSE: AVO] (&#147;AMO&#148;)
today announced final results of its &#147;Modified Dutch Auction&#148; tender offer (the
&#147;Offer&#148;) for up to $115.0 million aggregate principal amount at maturity (the
&#147;Offer Amount&#148;) of its outstanding 9-1/4% Senior Subordinated Notes due 2010
(the &#147;Notes&#148;). The Offer commenced on June 18, 2003 and expired at 12:00
midnight on July 18, 2003 (the &#147;Expiration Date&#148;). </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Based
on a final count by The Bank of New York, the depositary for the Offer, a total of
$177,640,000 aggregate principal amount at maturity of Notes was properly tendered by
holders of Notes as of the Expiration Date. In accordance with the terms of the Offer,
including the pro-ration terms thereof, AMO has accepted for payment the full $115.0
million aggregate principal amount at maturity of Notes subject to the Offer as set forth
below. The final purchase price was set at $1,150 per $1,000 aggregate principal amount at
maturity of Notes, the maximum offer price in the Offer. AMO will pay the same purchase
price for all Notes accepted for payment, resulting in an aggregate payment of
$132,250,000, plus accrued and unpaid interest thereon to, but not including, the date of
purchase. Due to the over-subscription, AMO has accepted and will purchase, in accordance
with the terms of the Offer, the full Offer Amount as follows: (i) all $107,140,000
aggregate principal amount at maturity of Notes tendered below the purchase price and (ii)
$7,860,000 aggregate principal amount at maturity of the $70,500,000 aggregate principal
amount at maturity of Notes tendered at the purchase price, which reflects a pro-ration
factor of 11.1489362%. Tenders made below the purchase price were not subject to
pro-ration. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Payment
for Notes properly tendered and accepted for purchase, and the return of all other Notes
tendered but not accepted for purchase, will be made promptly by The Bank of New York, the
depositary for the Offer. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Morgan
Stanley &amp; Co. Incorporated acted as exclusive dealer manager and Mellon Investor
Services LLC acted as information agent in connection with the Offer. </FONT></TD></TR></TABLE><BR>



<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>About
Advanced Medical Optics</B> <BR>Advanced
Medical Optics, Inc. (AMO) is a global leader in the development, manufacturing and
marketing of ophthalmic surgical and eye care products. The Company focuses on developing
a broad suite of innovative technologies and devices to address a wide range of eye
disorders. Products in the ophthalmic surgical line include foldable intraocular lenses,
phacoemulsification systems, viscoelastics and related products used in cataract surgery,
and microkeratomes used in LASIK procedures for refractive error correction. AMO owns or
has the rights to such well-known ophthalmic surgical product brands as PhacoFlex&reg;,
Clariflex&reg;, Array&reg; and Sensar&reg; foldable intraocular lenses, the Sovereign&reg;
phacoemulsification system and the Amadeus&#153; microkeratome. Products in the eye care
line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting
drops. Among the well-known eye care product brands the Company possesses are
COMPLETE&reg;, COMPLETE&reg; Blink-N-Clean&reg;, Consept&reg;F, Consept&reg; 1 Step,
Oxysept&reg; 1 Step, Ultracare&reg;, Ultrazyme&reg;, Total Care&reg; and blink&#153;.
Amadeus&#153; is a licensed product of, and a trademark of, SIS, Ltd. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Advanced
Medical Optics, Inc. is based in Santa Ana, California, and employs approximately 2,000
worldwide. The Company has operations in about 20 countries and markets products in
approximately 60 countries. For more information, visit the Company&#146;s web site at
www.amo-inc.com. </FONT></TD></TR></TABLE><BR>



<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Forward-Looking
Statements</B> <BR>This
press release contains forward-looking statements about AMO, including those relating to
the Offer. All forward-looking statements in this press release are based on estimates and
assumptions and represent AMO&#146;s judgment only as of the date of this press release.
Actual results may differ from current expectations based on a number of factors including
but not limited to changing market conditions and matters generally affecting the domestic
and global economy, such as changes in interest and currency exchange rates. Therefore,
the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any
intent or obligation to update these forward-looking statements. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Default" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Additional
information concerning these and other risk factors may be found in previous financial
press releases issued by AMO. AMO&#146;s public periodic filings with the Securities and
Exchange Commission, including the discussion under the heading &#147;Certain Factors and
Trends Affecting AMO and its Businesses&#148; in AMO&#146;s 2002 Form 10-K filed by AMO
with the Securities and Exchange Commission on March 14, 2003 and in AMO&#146;s Form 10-Q
for the quarter ended March 28, 2003 filed by AMO with the Securities and Exchange
Commission on May 5, 2003, also include information concerning these and other risk
factors. Copies of press releases and additional information about AMO are available on
the World Wide Web at www.amo-inc.com, or you can contact the AMO Investor Relations
Department by calling the number listed below. </FONT></TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>#&nbsp;&nbsp;#&nbsp;&nbsp;#&nbsp;&nbsp; </FONT></TD></TR>
</TABLE>
<BR>


</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "la310373.htm", "description": "FORM 8-K", "secsgml_size_bytes": 32026}]
{"company-data": {"conformed-name": "ADVANCED MEDICAL OPTICS INC", "cik": "0001168335", "assigned-sic": "5040", "irs-number": "33098682", "state-of-incorporation": "DE"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-31257", "film-number": "03798087"}, "business-address": {"street1": "2525 DUPONT DR.", "city": "IRVINE", "state": "CA", "zip": "92612", "phone": "7142464500"}}
8K Form
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
 REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 21, 2003
ADVANCED
MEDICAL OPTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
01-31257
33-0986820
(State or other jurisdiction of
incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1700
      E. St. Andrew Place
Santa Ana, CA
92705
(Address of principal executive offices)
(Zip Code)
Registrant's
telephone number, including area code: (714) 247-8200
(Former name or former address, if changed since last report)
Item
5.        Other Events and Required FD Disclosure.
On
July 21, 2003, the Registrant announced preliminary results of its modified Dutch auction
tender offer for its 9-1/4% Senior Subordinated Notes due 2010. The press release issued
with respect thereto is attached hereto as Exhibit 99.1 and by this reference incorporated
herein.
On
July 23, 2003, the Registrant announced final results of its modified Dutch auction tender
offer for its 9-1/4% Senior Subordinated Notes due 2010. The press release issued with
respect thereto is attached hereto as Exhibit 99.2 and by this reference incorporated
herein.
Item
7.            Financial Statements, Pro Forma Financial Information and Exhibits.
(c)
Exhibits.
99.1
Press release of Registrant, dated July 21, 2003, with respect to preliminary results of
modified Dutch auction tender offer.
99.2
Press release of Registrant, dated July 23, 2003, with respect to final results of
modified Dutch auction tender offer.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
ADVANCED MEDICAL OPTICS, INC.
Date:
July 23, 2003
By:
/s/ Aimee S. Weisner
Aimee S. Weisner, Corporate Vice President, General Counsel and Secretary
INDEX
TO EXHIBITS
Number
Exhibit
99.1
Press release of Registrant, dated July 21, 2003, with respect to preliminary results of
modified Dutch auction tender offer.
99.2
Press release of Registrant, dated July 23, 2003, with respect to final results of
modified Dutch auction tender offer.
Exhibit
99.1
FOR
IMMEDIATE RELEASE
Advanced
Medical Optics, Inc.
Contact:  Vince Scullin
(714) 247-8344
vince.scullin@amo-inc.com
ADVANCED
MEDICAL OPTICS, INC. ANNOUNCES
PRELIMINARY RESULTS OF MODIFIED DUTCH AUCTION TENDER
OFFER
FOR ITS 9-1/4% SENIOR SUBORDINATED NOTES
(SANTA
ANA, CA), July 21, 2003 — Advanced Medical Optics, Inc. [NYSE: AVO] ("AMO")
today announced preliminary results of its "Modified Dutch Auction" tender offer
(the "Offer") for up to $115.0 million aggregate principal amount at maturity
(the "Offer Amount") of its outstanding 9-1/4% Senior Subordinated Notes due
2010 (the "Notes"). The Offer commenced on June 18, 2003 and expired at 12:00
midnight on July 18, 2003 (the "Expiration Date").
As
of the Expiration Date, the Depositary for the Offer reported that approximately $177.6
million aggregate principal amount at maturity of Notes had been properly tendered by
holders of Notes (including $500,000 aggregate principal amount at maturity tendered
through notice of guaranteed delivery) at or below the maximum offer price of $1,150 per
$1,000 aggregate principal amount at maturity of Notes. Due to the over-subscription, in
accordance with the terms of the Offer, AMO expects to purchase (i) all Notes tendered
below the purchase price and (ii) Notes tendered at the purchase price on a pro rata basis
in an amount that will enable the Company to purchase the full $115.0 million aggregate
principal amount at maturity of Notes subject to the Offer. AMO will pay the same purchase
price for all Notes accepted for payment in the Offer. Based on the preliminary results,
AMO expects the purchase price to be the maximum offer price of $1,150 per $1,000
aggregate principal amount at maturity of Notes and expects the pro-ration factor to be
approximately 11%. The actual purchase price and pro-ration factor will be announced
promptly following completion of the verification process. Final determination of the
actual aggregate principal amount at maturity of Notes to be purchased is subject to final
delivery and final confirmation. Any Notes not accepted for payment will be promptly
returned to holders.
Morgan
Stanley & Co. Incorporated acted as exclusive dealer manager, Mellon Investor Services
LLC acted as information agent and The Bank of New York acted as depositary in connection
with the Offer.
About
Advanced Medical Optics
Advanced
Medical Optics, Inc. (AMO) is a global leader in the development, manufacturing and
marketing of ophthalmic surgical and eye care products. The Company focuses on developing
a broad suite of innovative technologies and devices to address a wide range of eye
disorders. Products in the ophthalmic surgical line include foldable intraocular lenses,
phacoemulsification systems, viscoelastics and related products used in cataract surgery,
and microkeratomes used in LASIK procedures for refractive error correction. AMO owns or
has the rights to such well-known ophthalmic surgical product brands as PhacoFlex®,
Clariflex®, Array® and Sensar® foldable intraocular lenses, the Sovereign®
phacoemulsification system and the Amadeus™ microkeratome. Products in the eye care
line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting
drops. Among the well-known eye care product brands the Company possesses are
COMPLETE®, COMPLETE® Blink-N-Clean®, Consept®F, Consept® 1 Step,
Oxysept® 1 Step, Ultracare®, Ultrazyme®, Total Care® and blink™.
Amadeus™ is a licensed product of, and a trademark of, SIS, Ltd.
Advanced
Medical Optics, Inc. is based in Santa Ana, California, and employs approximately 2,000
worldwide. The Company has operations in about 20 countries and markets products in
approximately 60 countries. For more information, visit the Company's web site at
www.amo-inc.com.
Forward-Looking
Statements
This press release contains forward-looking statements about AMO, including those relating to
the Offer. All forward-looking statements in this press release are based on estimates and
assumptions and represent AMO's judgment only as of the date of this press release.
Actual results may differ from current expectations based on a number of factors including
but not limited to changing market conditions and matters generally affecting the domestic
and global economy, such as changes in interest and currency exchange rates. Therefore,
the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any
intent or obligation to update these forward-looking statements.
Additional
information concerning these and other risk factors may be found in previous financial
press releases issued by AMO. AMO's public periodic filings with the Securities and
Exchange Commission, including the discussion under the heading "Certain Factors and
Trends Affecting AMO and its Businesses" in AMO's 2002 Form 10-K filed by AMO
with the Securities and Exchange Commission on March 14, 2003 and in AMO's Form 10-Q
for the quarter ended March 28, 2003 filed by AMO with the Securities and Exchange
Commission on May 5, 2003, also include information concerning these and other risk
factors. Copies of press releases and additional information about AMO are available on
the World Wide Web at www.amo-inc.com, or you can contact the AMO Investor Relations
Department by calling the number listed below.
#  #  #
Exhibit
99.2
FOR
IMMEDIATE RELEASE
Advanced
Medical Optics, Inc.
Contact:  Vince Scullin
(714) 247-8344
vince.scullin@amo-inc.com
ADVANCED
MEDICAL OPTICS, INC. ANNOUNCES
FINAL RESULTS OF MODIFIED DUTCH AUCTION TENDER OFFER
FOR ITS 9-1/4% SENIOR SUBORDINATED NOTES
(SANTA
ANA, CA), July 23, 2003 — Advanced Medical Optics, Inc. [NYSE: AVO] ("AMO")
today announced final results of its "Modified Dutch Auction" tender offer (the
"Offer") for up to $115.0 million aggregate principal amount at maturity (the
"Offer Amount") of its outstanding 9-1/4% Senior Subordinated Notes due 2010
(the "Notes"). The Offer commenced on June 18, 2003 and expired at 12:00
midnight on July 18, 2003 (the "Expiration Date").
Based
on a final count by The Bank of New York, the depositary for the Offer, a total of
$177,640,000 aggregate principal amount at maturity of Notes was properly tendered by
holders of Notes as of the Expiration Date. In accordance with the terms of the Offer,
including the pro-ration terms thereof, AMO has accepted for payment the full $115.0
million aggregate principal amount at maturity of Notes subject to the Offer as set forth
below. The final purchase price was set at $1,150 per $1,000 aggregate principal amount at
maturity of Notes, the maximum offer price in the Offer. AMO will pay the same purchase
price for all Notes accepted for payment, resulting in an aggregate payment of
$132,250,000, plus accrued and unpaid interest thereon to, but not including, the date of
purchase. Due to the over-subscription, AMO has accepted and will purchase, in accordance
with the terms of the Offer, the full Offer Amount as follows: (i) all $107,140,000
aggregate principal amount at maturity of Notes tendered below the purchase price and (ii)
$7,860,000 aggregate principal amount at maturity of the $70,500,000 aggregate principal
amount at maturity of Notes tendered at the purchase price, which reflects a pro-ration
factor of 11.1489362%. Tenders made below the purchase price were not subject to
pro-ration.
Payment
for Notes properly tendered and accepted for purchase, and the return of all other Notes
tendered but not accepted for purchase, will be made promptly by The Bank of New York, the
depositary for the Offer.
Morgan
Stanley & Co. Incorporated acted as exclusive dealer manager and Mellon Investor
Services LLC acted as information agent in connection with the Offer.
About
Advanced Medical Optics
Advanced
Medical Optics, Inc. (AMO) is a global leader in the development, manufacturing and
marketing of ophthalmic surgical and eye care products. The Company focuses on developing
a broad suite of innovative technologies and devices to address a wide range of eye
disorders. Products in the ophthalmic surgical line include foldable intraocular lenses,
phacoemulsification systems, viscoelastics and related products used in cataract surgery,
and microkeratomes used in LASIK procedures for refractive error correction. AMO owns or
has the rights to such well-known ophthalmic surgical product brands as PhacoFlex®,
Clariflex®, Array® and Sensar® foldable intraocular lenses, the Sovereign®
phacoemulsification system and the Amadeus™ microkeratome. Products in the eye care
line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting
drops. Among the well-known eye care product brands the Company possesses are
COMPLETE®, COMPLETE® Blink-N-Clean®, Consept®F, Consept® 1 Step,
Oxysept® 1 Step, Ultracare®, Ultrazyme®, Total Care® and blink™.
Amadeus™ is a licensed product of, and a trademark of, SIS, Ltd.
Advanced
Medical Optics, Inc. is based in Santa Ana, California, and employs approximately 2,000
worldwide. The Company has operations in about 20 countries and markets products in
approximately 60 countries. For more information, visit the Company's web site at
www.amo-inc.com.
Forward-Looking
Statements
This
press release contains forward-looking statements about AMO, including those relating to
the Offer. All forward-looking statements in this press release are based on estimates and
assumptions and represent AMO's judgment only as of the date of this press release.
Actual results may differ from current expectations based on a number of factors including
but not limited to changing market conditions and matters generally affecting the domestic
and global economy, such as changes in interest and currency exchange rates. Therefore,
the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any
intent or obligation to update these forward-looking statements.
Additional
information concerning these and other risk factors may be found in previous financial
press releases issued by AMO. AMO's public periodic filings with the Securities and
Exchange Commission, including the discussion under the heading "Certain Factors and
Trends Affecting AMO and its Businesses" in AMO's 2002 Form 10-K filed by AMO
with the Securities and Exchange Commission on March 14, 2003 and in AMO's Form 10-Q
for the quarter ended March 28, 2003 filed by AMO with the Securities and Exchange
Commission on May 5, 2003, also include information concerning these and other risk
factors. Copies of press releases and additional information about AMO are available on
the World Wide Web at www.amo-inc.com, or you can contact the AMO Investor Relations
Department by calling the number listed below.
#  #  #